Liquidia Corp (LQDA) Stock
3 of the hedge funds AlphaScala tracks reported LQDA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $101.07M. Company insiders reported 0 open-market buys and 21 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own LQDA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.27M | $101.07M | +45% |
| Renaissance Technologies Jim Simons (founder) | 232K | $18.53M | +2769% |
| Marshall Wace | 73K | $5.84M | -75% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Liquidia Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Adair Jason | Chief Business Officer | SELL | 7.3K | $208K |
| Oct 12, 26 | Boyle Dana | Chief Accounting Officer | SELL | 5.9K | $168K |
| Oct 12, 26 | Jeffs Roger | Chief Executive Officer | SELL | 32.7K | $933K |
| Oct 12, 26 | Kaseta Michael | CFO and COO | SELL | 18.9K | $539K |
| Oct 12, 26 | Khindri Sanjeev | Chief Development Officer | SELL | 1.1K | $31K |
| Oct 12, 26 | Krepp Sarah | Chief Human Resource Officer | SELL | 5.2K | $149K |
| Oct 12, 26 | Moomaw Scott | Chief Commercial Officer | SELL | 8.9K | $252K |
| Oct 12, 26 | Saggar Rajeev | Chief Medical Officer | SELL | 9.2K | $263K |
| Oct 12, 26 | Schundler Russell | General Counsel | SELL | 13.7K | $390K |
| Oct 5, 26 | Bloch Stephen M | Director | SELL | 235.5K | $6.4M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →LQDA price chart
Powered by TradingViewWhat does Liquidia Corp do?
Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in pulmonary hypertension. Its key product, Yutrepia, is an inhaled dry powder formulation of treprostinil used for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, delivered via a user-friendly inhalation device to support chronic outpatient management. Liquidia also commercializes and develops treprostinil-based therapies in other formulations, including continuous infusion and investigational liposomal and inhaled sustained-release products, often under licensing collaborations. By concentrating on specialized cardiopulmonary indications and leveraging drug-delivery innovation, Liquidia plays a targeted role within the U.S. pharmaceuticals and biotech sector, serving pulmonologists, specialty clinics, and hospital systems involved in advanced respiratory and vascular care. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates within the broader healthcare ecosystem as a niche provider of advanced pulmonary hypertension treatments.